Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

J. A. Johnson*, K. E. Caudle, L. Gong, M. Whirl-Carrillo, C. M. Stein, S. A. Scott, M. T. Lee, B. F. Gage, S. E. Kimmel, M. A. Perera, J. L. Anderson, M. Pirmohamed, T. E. Klein, N. A. Limdi, L. H. Cavallari, M. Wadelius

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

235 Scopus citations

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Original languageEnglish (US)
Pages (from-to)397-404
Number of pages8
JournalClinical pharmacology and therapeutics
Volume102
Issue number3
DOIs
StatePublished - Sep 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update'. Together they form a unique fingerprint.

Cite this